Clinical Observation of Flupentixol and Melitracen Combined with Rabeprazole in the Treatment of Reflux Esophagitis

OBJECTIVE:To observe clinical efficacy and safety of flupentixol and melitracen combined with rabeprazole in the treatment of reflux esophagitis(RE). METHODS:58 RE patients were randomly divided into control group and observation group with 29 patients in each group. Control group received Rabeprazole sodium enteric-coated tablets 10 mg orally,twice a day,morning and 30 min before bed;observation group was additionally given flupentixol and melitracen orally,once a day,at 10 o'clock in the morning on the basis of control group. Treatment course of 2 groups lasted for 8 weeks. Clinical efficacies of 2 groups were observed,and total clinical symptom score,HAMA score,HAMD score and ADR of 2 groups were observed before and after treatment. RESULTS:The total effective rate of observation group was significantly higher than that of control group;there was statistically significant difference(P0.05). Total clinical symptom score and HAMA score,HAMD score of 2 groups had no statistically significant difference before treatment(P0.05). Those of 2 groups after treatment were significantly lower than before,and the observation group was lower than the control group;there was statistically significant difference(P0.05 or P0.01). No obvious ADR was found in 2 groups during treatment. CONCLUSIONS:Flupentixol and melitracen combined with rabeprazole is more effective than rabeprazole alone in the treatment of RE,and they have similar safety.